Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses

Takumi Kumai, Sujin Lee, Hyun Il Cho, Hussein Sultan, Hiroya Kobayashi, Yasuaki Harabuchi, Esteban Celis

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Substantial evidence indicates that immunotherapy is a feasible and effective approach for the treatment of numerous types of cancer. Among various immunotherapy options, peptide vaccines to generate antitumor T cells appear as promising candidates, because of their cost effectiveness and ease of implementation. Nevertheless, most peptide vaccines are notorious for being weekly immunogenic and, thus, optimization of the vaccination strategy is essential to achieve therapeutic effectiveness. In addition, effective peptide vaccines must stimulate bothCD8cytotoxic and CD4 helper T lymphocytes. Our group has been successful in designing effective peptide vaccination strategies for inducing CD8 T-cell responses in mouse tumor models. Here, we describe a somewhat similar, but distinct, peptide vaccination strategy capable of generating vast CD4 T-cell responses by combining synthetic peptides with toll-like receptor (TLR) agonists and OX40/CD40 costimulation. This vaccination strategy was efficient in overcoming immune tolerance to a self-tumor-associated antigen and generated significant antitumor effects in a mouse model of malignant melanoma. The optimized peptide vaccine also allowed the expansion of adoptively transferred CD4 T cells without the need for lymphodepletion and IL2 administration, generating effective antimelanoma responses through the enhancement of proliferative and antiapoptotic activities of CD4 T cells. These results have practical implications in the design of more effective T-cell-based immunotherapies.

Original languageEnglish (US)
Pages (from-to)72-83
Number of pages12
JournalCancer Immunology Research
Volume5
Issue number1
DOIs
StatePublished - Jan 2017

Fingerprint

Subunit Vaccines
T-Lymphocytes
Vaccination
Immunotherapy
Peptides
Immune Tolerance
Toll-Like Receptors
Neoplasm Antigens
Helper-Inducer T-Lymphocytes
Cost-Benefit Analysis
Interleukin-2
Melanoma
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. / Kumai, Takumi; Lee, Sujin; Cho, Hyun Il; Sultan, Hussein; Kobayashi, Hiroya; Harabuchi, Yasuaki; Celis, Esteban.

In: Cancer Immunology Research, Vol. 5, No. 1, 01.2017, p. 72-83.

Research output: Contribution to journalArticle

Kumai, Takumi ; Lee, Sujin ; Cho, Hyun Il ; Sultan, Hussein ; Kobayashi, Hiroya ; Harabuchi, Yasuaki ; Celis, Esteban. / Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. In: Cancer Immunology Research. 2017 ; Vol. 5, No. 1. pp. 72-83.
@article{355bd880f6cf49e3b5c60244fea04f1b,
title = "Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses",
abstract = "Substantial evidence indicates that immunotherapy is a feasible and effective approach for the treatment of numerous types of cancer. Among various immunotherapy options, peptide vaccines to generate antitumor T cells appear as promising candidates, because of their cost effectiveness and ease of implementation. Nevertheless, most peptide vaccines are notorious for being weekly immunogenic and, thus, optimization of the vaccination strategy is essential to achieve therapeutic effectiveness. In addition, effective peptide vaccines must stimulate bothCD8cytotoxic and CD4 helper T lymphocytes. Our group has been successful in designing effective peptide vaccination strategies for inducing CD8 T-cell responses in mouse tumor models. Here, we describe a somewhat similar, but distinct, peptide vaccination strategy capable of generating vast CD4 T-cell responses by combining synthetic peptides with toll-like receptor (TLR) agonists and OX40/CD40 costimulation. This vaccination strategy was efficient in overcoming immune tolerance to a self-tumor-associated antigen and generated significant antitumor effects in a mouse model of malignant melanoma. The optimized peptide vaccine also allowed the expansion of adoptively transferred CD4 T cells without the need for lymphodepletion and IL2 administration, generating effective antimelanoma responses through the enhancement of proliferative and antiapoptotic activities of CD4 T cells. These results have practical implications in the design of more effective T-cell-based immunotherapies.",
author = "Takumi Kumai and Sujin Lee and Cho, {Hyun Il} and Hussein Sultan and Hiroya Kobayashi and Yasuaki Harabuchi and Esteban Celis",
year = "2017",
month = "1",
doi = "10.1158/2326-6066.CIR-16-0194",
language = "English (US)",
volume = "5",
pages = "72--83",
journal = "Cancer Immunity",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses

AU - Kumai, Takumi

AU - Lee, Sujin

AU - Cho, Hyun Il

AU - Sultan, Hussein

AU - Kobayashi, Hiroya

AU - Harabuchi, Yasuaki

AU - Celis, Esteban

PY - 2017/1

Y1 - 2017/1

N2 - Substantial evidence indicates that immunotherapy is a feasible and effective approach for the treatment of numerous types of cancer. Among various immunotherapy options, peptide vaccines to generate antitumor T cells appear as promising candidates, because of their cost effectiveness and ease of implementation. Nevertheless, most peptide vaccines are notorious for being weekly immunogenic and, thus, optimization of the vaccination strategy is essential to achieve therapeutic effectiveness. In addition, effective peptide vaccines must stimulate bothCD8cytotoxic and CD4 helper T lymphocytes. Our group has been successful in designing effective peptide vaccination strategies for inducing CD8 T-cell responses in mouse tumor models. Here, we describe a somewhat similar, but distinct, peptide vaccination strategy capable of generating vast CD4 T-cell responses by combining synthetic peptides with toll-like receptor (TLR) agonists and OX40/CD40 costimulation. This vaccination strategy was efficient in overcoming immune tolerance to a self-tumor-associated antigen and generated significant antitumor effects in a mouse model of malignant melanoma. The optimized peptide vaccine also allowed the expansion of adoptively transferred CD4 T cells without the need for lymphodepletion and IL2 administration, generating effective antimelanoma responses through the enhancement of proliferative and antiapoptotic activities of CD4 T cells. These results have practical implications in the design of more effective T-cell-based immunotherapies.

AB - Substantial evidence indicates that immunotherapy is a feasible and effective approach for the treatment of numerous types of cancer. Among various immunotherapy options, peptide vaccines to generate antitumor T cells appear as promising candidates, because of their cost effectiveness and ease of implementation. Nevertheless, most peptide vaccines are notorious for being weekly immunogenic and, thus, optimization of the vaccination strategy is essential to achieve therapeutic effectiveness. In addition, effective peptide vaccines must stimulate bothCD8cytotoxic and CD4 helper T lymphocytes. Our group has been successful in designing effective peptide vaccination strategies for inducing CD8 T-cell responses in mouse tumor models. Here, we describe a somewhat similar, but distinct, peptide vaccination strategy capable of generating vast CD4 T-cell responses by combining synthetic peptides with toll-like receptor (TLR) agonists and OX40/CD40 costimulation. This vaccination strategy was efficient in overcoming immune tolerance to a self-tumor-associated antigen and generated significant antitumor effects in a mouse model of malignant melanoma. The optimized peptide vaccine also allowed the expansion of adoptively transferred CD4 T cells without the need for lymphodepletion and IL2 administration, generating effective antimelanoma responses through the enhancement of proliferative and antiapoptotic activities of CD4 T cells. These results have practical implications in the design of more effective T-cell-based immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=85016132017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016132017&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-16-0194

DO - 10.1158/2326-6066.CIR-16-0194

M3 - Article

C2 - 27941004

AN - SCOPUS:85016132017

VL - 5

SP - 72

EP - 83

JO - Cancer Immunity

JF - Cancer Immunity

SN - 2326-6066

IS - 1

ER -